Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance

Abstract Visceral leishmaniasis (VL) remains a major public health problem worldwide. Cytokine balance is thought to play a critical role in the development of this disease. Here, we perform a prospective exploratory study addressing whether simultaneous assessment of circulating levels of different...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Théo Araújo-Santos, Bruno B. Andrade, Leonardo Gil-Santana, Nívea F. Luz, Priscila L. dos Santos, Fabrícia A. de Oliveira, Meirielly Lima Almeida, Roseane Nunes de Santana Campos, Patrícia T. Bozza, Roque P. Almeida, Valeria M. Borges
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/799be9b2280e4569a562fe387b5f87b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:799be9b2280e4569a562fe387b5f87b2
record_format	dspace
spelling	oai:doaj.org-article:799be9b2280e4569a562fe387b5f87b22021-12-02T15:18:52ZAnti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance10.1038/s41598-017-04595-82045-2322https://doaj.org/article/799be9b2280e4569a562fe387b5f87b22017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04595-8https://doaj.org/toc/2045-2322Abstract Visceral leishmaniasis (VL) remains a major public health problem worldwide. Cytokine balance is thought to play a critical role in the development of this disease. Here, we perform a prospective exploratory study addressing whether simultaneous assessment of circulating levels of different lipid mediators and cytokines could highlight specific pathways involved with VL pathogenesis. VL patients displayed substantial increases in serum levels of Prostaglandin F2α (PGF2α), Leukotriene B4 (LTB4), Resolvin D1 (RvD1), IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α compared with uninfected endemic control group, while exhibiting decreased levels of TGF-β1. Hierarchical cluster analysis of the prospective changes in the expression level of theses parameters upon anti-Leishmania treatment initiation revealed that the inflammatory profile observed in active disease gradually changed over time and was generally reversed at day 30 of therapy. Furthermore, not only the individual concentrations of most of the inflammatory biomarkers changed upon treatment, but the correlations between those and several biochemical parameters used to characterize VL disease activity were also modified over time. These results demonstrate that an inflammatory imbalance hallmarks active VL disease and open perspective for manipulation of these pathways in future studies examining a potential host-directed therapy against VL.Théo Araújo-SantosBruno B. AndradeLeonardo Gil-SantanaNívea F. LuzPriscila L. dos SantosFabrícia A. de OliveiraMeirielly Lima AlmeidaRoseane Nunes de Santana CamposPatrícia T. BozzaRoque P. AlmeidaValeria M. BorgesNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Théo Araújo-Santos Bruno B. Andrade Leonardo Gil-Santana Nívea F. Luz Priscila L. dos Santos Fabrícia A. de Oliveira Meirielly Lima Almeida Roseane Nunes de Santana Campos Patrícia T. Bozza Roque P. Almeida Valeria M. Borges Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
description	Abstract Visceral leishmaniasis (VL) remains a major public health problem worldwide. Cytokine balance is thought to play a critical role in the development of this disease. Here, we perform a prospective exploratory study addressing whether simultaneous assessment of circulating levels of different lipid mediators and cytokines could highlight specific pathways involved with VL pathogenesis. VL patients displayed substantial increases in serum levels of Prostaglandin F2α (PGF2α), Leukotriene B4 (LTB4), Resolvin D1 (RvD1), IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α compared with uninfected endemic control group, while exhibiting decreased levels of TGF-β1. Hierarchical cluster analysis of the prospective changes in the expression level of theses parameters upon anti-Leishmania treatment initiation revealed that the inflammatory profile observed in active disease gradually changed over time and was generally reversed at day 30 of therapy. Furthermore, not only the individual concentrations of most of the inflammatory biomarkers changed upon treatment, but the correlations between those and several biochemical parameters used to characterize VL disease activity were also modified over time. These results demonstrate that an inflammatory imbalance hallmarks active VL disease and open perspective for manipulation of these pathways in future studies examining a potential host-directed therapy against VL.
format	article
author	Théo Araújo-Santos Bruno B. Andrade Leonardo Gil-Santana Nívea F. Luz Priscila L. dos Santos Fabrícia A. de Oliveira Meirielly Lima Almeida Roseane Nunes de Santana Campos Patrícia T. Bozza Roque P. Almeida Valeria M. Borges
author_facet	Théo Araújo-Santos Bruno B. Andrade Leonardo Gil-Santana Nívea F. Luz Priscila L. dos Santos Fabrícia A. de Oliveira Meirielly Lima Almeida Roseane Nunes de Santana Campos Patrícia T. Bozza Roque P. Almeida Valeria M. Borges
author_sort	Théo Araújo-Santos
title	Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_short	Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_full	Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_fullStr	Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_full_unstemmed	Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
title_sort	anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/799be9b2280e4569a562fe387b5f87b2
work_keys_str_mv	AT theoaraujosantos antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT brunobandrade antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT leonardogilsantana antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT niveafluz antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT priscilaldossantos antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT fabriciaadeoliveira antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT meiriellylimaalmeida antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT roseanenunesdesantanacampos antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT patriciatbozza antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT roquepalmeida antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance AT valeriamborges antiparasitetherapydriveschangesinhumanvisceralleishmaniasisassociatedinflammatorybalance
_version_	1718387453898784768

Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance

Ejemplares similares